BioCurex Files New RECAF Patent

31-Jul-2008

BioCurex Inc. announced that it has filed a new patent application to protect certain methods of purifying and detecting RECAF in bodily fluids. The patent application also includes what the company believes - based on available information - to be new methods for tumor imaging and therapy based on RECAF.

The patent application has been filed as a provisional patent application. This means that the patent application remains undisclosed for up to 18 months at the owner's discretion, thus providing one more year of protection, and, assuming the patent application is granted, therefore providing further RECAF technology protection for another 21 years.

This patent application contains critical methods necessary for manufacturing RECAF tests as well as for the generation of synthetic products to be used to target RECAF in-vivo (inside the body). These products can be manufactured at low cost, in highly pure form and without the need to use biological systems; thus eliminating the possibility of carrying infectious diseases to the recipients.

As a result of the protection provided by this new patent application, the company has forfeited its former patent application in Japan, where differences in patent law as compared to the USA and the EU, have resulted in unanticipated resistance to approval. BioCurex holds granted patents in the USA, the European Union, Russia, Australia, Norway and China at this time.

The new application will soon be extended through the Patent Cooperation Treaty to the most populated and developed countries with highest market potential, as we have done previously.

Dr. Moro, BioCurex's CEO stated: 'This new patent application is the result of several years of intense work and it reflects the value added to our company resulting from that investment in time and money. We - and our licensees - have been using technology contained in our issued patents for some time now, in our daily work. There are other improvements that will be the subject of new patent applications to be filed in the near future. This strategy is intended to stake the RECAF technology with a number of patent claims in a way that will prevent others from circumventing our patents as well as extending the protection period of our technology. '

https://www.bionity.com/en/news/85269/biocurex-files-new-recaf-patent.html